Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Account Payables
Amounts the company owes suppliers for goods and services received.
Apogee Therapeutics, Inc.NASDAQ: APGE
Account Payables · Q2 FY2026 · quarter ended Jun 2026
Account payables falls 45.8% from a year ago
Account payables stood at $3.08M at the end of Q2 FY2026, down 45.8% from a year earlier and up 149.0% from the prior quarter. Over 3 fiscal years it compounded at +42.9% a year.
Context
- Account payables amounted to 0.2% of total assets at the end of Q2 FY2026, down 0.6 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -45.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 1.22M USD
- Year-over-year change
- +14.0%
- 3-year CAGR
- +42.9%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.22M | +14.0% |
| FY2024 | 2024-12-31 | 1.07M | -50.0% |
| FY2023 | 2023-12-31 | 2.14M | +412.7% |
| FY2022 | 2022-12-31 | 418K | — |
Account Payables vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -45.8% is the 9th highest of 10, against a peer median of -11.5%.
- Account payables amounts to 0.2% of total assets for APGE, versus a peer median of 1.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $136.69M USD | +27.3% | +29.0% | 12.7% | |
AAPGAscentage Pharma Group International | Dec 2025 | CN¥106.81M CNY | +16.1% | +3.8% | 2.7% |
| Sep 2026 | $72M USD | -29.7% | +36.8% | 4.3% | |
| Mar 2026 | $42M USD | -11.5% | -10.5% | 3.2% | |
| Mar 2026 | $10.66M USD | +107.7% | -18.2% | 1.7% | |
| Sep 2026 | $9.77M USD | +6.3% | +79.7% | 0.9% | |
| Jun 2026 | $8.09M USD | -27.5% | +34.6% | 1.0% | |
IRONDisc Medicine, Inc. | Sep 2026 | $6.07M USD | -16.4% | -17.7% | 0.9% |
| Jun 2026 | $3.08M USD | -45.8% | +42.9% | 0.2% | |
| Sep 2026 | $1.93M USD | -57.7% | -22.9% | 0.2% | |
| Peer median (excluding APGE) | — | -11.5% | +3.8% | 1.7% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.